G1 Therapeutics, Inc. 4
4 · G1 Therapeutics, Inc. · Filed May 24, 2017
Insider Transaction Report
Form 4
Strum Jay
Chief Scientific Officer
Transactions
- Conversion
Common Stock
2017-05-22+16,666→ 58,569 total - Conversion
Series 1 Preferred
2017-05-22−50,000→ 0 total→ Common Stock (16,666 underlying)
Footnotes (2)
- [F1]The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock converted to Common Stock on a 1-for-3 basis.
- [F2]The Series 1 Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.